Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FHIT | P49789 | 5/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444133 | 0.96 | P2RY1 (0.48) | FHITP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL21263944 | 0.94 | FHIT (0.40) | FHITP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL21263960 | 0.90 | P2RY1 (0.41) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| SCHEMBL24258614 | 0.89 | POLB (0.49) | FHITP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL24258604 | 0.87 | POLB (0.41) | FHITP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL24258615 | 0.86 | RNASEL (0.38) | FHITP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL21263871 | 0.86 | POLB (0.49) | FHITP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL24258651 | 0.84 | RNASEL (0.45) | — | |
| SCHEMBL24258636 | 0.83 | RNASEL (0.42) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| SCHEMBL24258653 | 0.80 | NT5E (0.37) | FHITP2RY1P2RY2SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | FHIT 4468/4885P2RY1 1124/4885P2RY2 1259/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | FHIT 4468/4885P2RY1 1124/4885P2RY2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.